New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
08:38 EDTROSGRosetta Genomics announces its cancer test received provider status
Rosetta Genomics announces the Rosetta Cancer Origin Test has received in-network provider status with Highmark Health Services, a subsidiary of Highmark. This test for the identification of the tumor origin in Cancer of Unknown or Uncertain Primary is now available to eligible Highmark Health Services members as an in-network service based on the individual member's benefits.
News For ROSG From The Last 14 Days
Check below for free stories on ROSG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
09:31 EDTROSGRosetta Genomics receives final NY approval for its kidney cancer test
Subscribe for More Information
July 10, 2014
09:03 EDTROSGRosetta Genomics receives patent for ovarian cancer treatment
Rosetta Genomics announces receipt of a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application No. 13/977,797, entitled "Compositions and Methods for Treatment of Ovarian Cancer." The patent relates to inhibition of miR-210 for the treatment of ovarian cancer. Treatment for advanced ovarian carcinoma is typically based on the combination of surgery and chemotherapy. The objective of surgical intervention in patients suffering from advanced disease is to perform cyto-reduction to minimal residual disease in the abdominal cavity. Surgery is followed by adjuvant platinum based chemotherapy. Although 80%-90% of patients initially respond to first line treatment, most will either progress during therapy or recur after complete remission. Ovarian cancer causes more deaths than any other gynecologic cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use